Uncertainty regarding pathogenic mechanisms has been a major impediment to effective prevention and treatment for human neurologic diseases such as multiple sclerosis, tropical spastic paraparesis, and AIDS demyelinating disease. Here, we implicate lymphotoxin (LT) (tumor necrosis factor (3 [TNF-0]) and TNF-ci in experimental allergic encephalomyelitis (EAE), a murine model of an autoimmune demyelinating disease. In this communication, we report that treatment of recipient mice with an antibody that neutralizes IT and TNF-a prevents transfer of clone-mediated EAE . LNC-8, a myelin basic protein-specific T cell line, produces high levels of IT and TNF-ot after activation by concanavalin A, antibody to the CD-3e component of the T cell receptor, or myelin basic protein presented in the context of syngeneic spleen cells . LNC-8 cells transfer clinical signs of EAE. When LNC-8 recipient mice were also treated with TN3 .19 .12, a monoclonal antibody that neutralizes IT and TNF-ci, the severity of the transferred EAE was reduced, while control antibodies did not alter the disease . The effect of anti-LT/TNF-cx treatment was long lived and has been sustained for 5 mo. These findings suggest that IT and TNF-ci and the T cells that produce them play an important role in EAE.
I
t has been suggested that the cytokines lymphotoxin (LT)' (TNF-a) and TNF-ot could contribute to pathogenesis in several human neurologic diseases, including multiple sclerosis (MS) (1) and AIDS dementia (2) . If that were the case, inhibition of the induction or activity of such cytokines might alleviate the tissue damage and demyelination associated with these diseases . In this study, we test the hypothesis that IT and TNF-cx are involved in experimental allergic encephalomyelitis (EAE), a murine model for MS, and demonstrate that inhibition of their activity prevents transfer of clinical signs of this paralytic disease.
IT and TNF-ci are genetically related cytokines with several activities that could contribute to demyelinating diseases. TNF-cx is produced by macrophages after stimulation with LPS, whereas both IT and TNF-ci are released by T cells activated by antigen or infection with some viruses, including human T cell leukemia virus type I (HTLVI) (3, 4) . IT and TNF-ot activities appear to be beneficial in defense against tumors and virus-infected cells (3) , and detrimental in their ' Abbreviations used in this paper . EAE, experimental allergic encephalomyelitis ; HTLV1, human T cell leukemia virus type I ; LT, lymphotoxin ; MBP, myelin basic protein ; MS, multiple sclerosis. association with cachexia (5) and (for TNF-a) in the pathogenesis of cerebral malaria (6) . Evidence has accumulated that supports but does not yet prove a role for IT and TNF-ac in certain neurologic diseases . One of the earliest descriptions of IT was derived from a study of lymphocytes of rats with EAE (7) . TNF-ct causes demyelination and death of oligodendrocytes in vitro (8) . Further corroboration and a suggestion for the biologic relevance of these observations is indicated by the recent description of TNF-ci in MS plaques (9) . The high levels of IT produced by HTLVI-infected T cell lines (10-12) is also consistent with an involvement of IT in tropical spastic paraparesis, a neurologic disease associated with infection with that human retrovirus .
In related studies (13, 14) , we have presented circumstantial evidence for a role of IT in EAE. A series of myelin basic protein (MBP-reactive) PL/J T cell clones had identical antigen fine specificity and MHC restriction, used the same TCR V(3 gene (15) , and produced Ilr2 in response to the encephalitogenic peptide (amino acids 1-11) of MBP presented in the context of H-2u. Despite these similarities, the clones varied in their ability to transfer EAE, and this was positively correlated with the amount of LT/TNF-cx cytotoxic activity and the amount of IT mRNA that they produced . Clones that transferred EAE efficiently, as assessed by incidence of disease, severity of clinical signs, and day of onset, produced high levels of cytotoxic factors (256 U) and mRNA for LT. Those that did not transfer disease produced low or undetectable levels (0-16 U) of cytotoxic activity and IT mRNA. The correlation with TNF-a was not as clear. Most clones that made IT mRNA also made TNF-a mRNA . However, one clone made high levels of TNT-a mRNA, but did not secrete cytotoxic material, and did not transfer disease particularly well . No correlation was found between IFN-'Y and IL-2 production and encephalitogenicity.
In this communication, we present additional data that support the hypothesis that IT and/or TNF-a are involved in the pathogenesis of EAE . These results obtained with the SJL/J murine model of EAE indicate that inhibition of IT and TNF-a reduces the severity of disease symptoms transferred by a T cell line. One implication of these results is that inhibition of these cytokines might alleviate clinical signs in certain immunologically mediated human neurologic diseases.
Materials and Methods LNC 8 T Cell Line. LNC-8 was derived from the pophteal lymph nodes of an SJL mouse immunized with porcine MBP. LNC-8 was maintained with biweekly addition of human rIIr2 (Amgen Biologicals, Thousand Oaks, CA) and stimulated with porcine MBP (101Lg/ml ; Calbiochem-Behring Corp., San Diego, CA) and irradiated SJL splenocytes every other week.
Activation of LT and TNF-a Production. LNC-8 cells (2 x 106 /ml) were incubated in medium that contained 10% FCS alone, or were supplemented with Con A (5 tug/ml), or 25 or 1001Ag/ml porcine MBP and irradiated syngeneic SJL spleen cells. For stimulation with anti-CD3, LNC-8 cells were added as above to tissue culture flasks that had been incubated overnight with anti-CD3 e antibody YCD3-1 (16) (23) . The filters were washed twice for 15 min at 55°C with 0.2x SSC and 0.1% SDS, and exposed to XAR film with intensifying screens .at -70°C. Transfer and Evaluation of EAE. LNC-8 cells were stimulated with MBP (10 pg/ml) and spleen cells for 3 d . The cells were then exposed to 2 U/ml 11,2 for 1 d . After that time, 7 .5-12 x 106 LNC-8 cells were injected intraperitoneally or intravenously as indicated in individual experiments. The mice were divided into groups and, 48 h later, injected with PBS, hamster control antibody L2D39, rat anti-IL4 antibody 11B11 (24) 
Results
Characteristics ofLNC-8 Cells. The IIr2-dependent T cell line LNC-8 used in the present studies to transfer EAE proliferates in response to MBP in the context of H-2' . It proliferates to all three major pepsin-digested fractions of MBP (data not shown) . One of these fractions includes the peptide, which is encephalitogenic for SJL/J mice, that lies in the COON-terminal end of the MBP molecule (25). We have found by FACS analysis that -50% of LNC-8 T cells stain with KJ23a, an antibody that reacts with the Va17a gene product of the TCR (Fig. 1 ) . This TCR gene usage is consistent with the observation that V017a and at least one other as yet undefined Vii gene are utilized by encephalitogenic SJL clones (26) .
LT and TNF-a Production by LNC-8 Cells. When LNC-8 cells are stimulated by Con A, they produce mRNA for several cytokines, including IFN--y and GM-CSF (data not shown) and IT and TNF-ca (Fig. 2) . Of particular interest is the fact that in the RNA samples from stimulated LNC-8 cells IT mRNA appeared to be at higher abundance than TNF-tx mRNA, and that the T cell line made considerably more IT and TNF mRNA than do Con A-activated spleen cells . There are actually several molecular species of LNC-8 RNA that hybridize with both the IT and TNF-a cDNA probes. One high molecular weight species (-3 kb) hybridizes with both probes and could represent an IT promoter-regulated transcript driven through the entire 6-kb TNF-a/(3 gene complex within the MHC on mouse chromosome 17 (27, 28) .
Culture supernatants from LNC-8 cells activated by several different methods contained cytotoxic activity against WEHI 164 cells, a target for both IT and TNF-a (Table 1) . Because the bioassay does not distinguish between the two cytokines, the results are expressed as LT/TNF-a activity. LNC-8 cells did not secrete LT/TNF unless activated . They ' LNC-8 cells were incubatd for 8 h in growth media plus 10% FCS.
Conditions of stimulation were as indicated in Materials and Methods. Exp. 1, MBP concentration was 25 lAg/ml ; Exp. 2, MBP was 100 /~g/ml . t LT/TNF units were determined by cytotoxic effect against WEHI 164 cells.
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Ruddle et al . Table 1 were positive for both IT and TNF-at mRNA, with usually higher accumulations of IT mRNA, as in Fig. 2 . Though it is not possible to distinguish between IT and TNF-a in the biologic assay, it is likely that the WEHI 164 killing in the experiments reported here is due to both cytokines since the activated LNC-8 cells made both mRNAs . In other studies, we have observed that the kinetics of IT and TNF-a mRNA production can vary in individual T cell clones, and the cytotoxic activity attributable to the individual cytokines varies with activation time . Neutralization ofLNC-8 Cytotoxic Activity byAnti-LT/TNEa Antibody. In a previous publication (18), we described a hamster mAb, TN3 .19.12, that reacts both with IT and TNF-a derived from supernatants of T cell clones and with TNF-a derived from macrophage culture supernatants . This antibody also neutralized the cytotoxic activity secretedby LNC-8 cells, indicating that the WEHI 164 killing activity is due to IT and/or TNF-cx . TN3 .19 .12 anti-LT/TNF-at antibody completely neutralized WEHI 164 cytotoxic activity of supernatants obtained after all methods of activation of LNC-8 cells, including antigen plus spleen cells (Fig. 3) , Con A, and anti-CD3 antibody. this dose of cells was dramatically inhibited with one injection of anti-LT/TNF-or. As indicated in Table 2 , the average disease score was 3.9 for the PBS-treated group; 3.3 for the anti-Ilr4-treated group, and 0.2 for the anti-LTTNF-a treated group (the latter score again below clinically detectable disease) . The incidence of disease was also reduced from 89% in the PBS treated group to 20% in the anti-LT/TNFLu group. The highest score of disease was 1 in this group. Histological evaluation of mice that received LNC-8 cells and TN3 .19 .12 that remained clinically normal revealed that some of these mice showed no evidence of cellular infiltration or abnormality, while others showed meningeal infiltration and mild perivascular cuffing . All mice from the group that received LNC-8 cells and control antibodies or PBS that were examined had histologic signs of cuffing and infiltration consistent with their clinical signs (Fig. 4) .
The inhibition oftransfer of EAE by treatment with anti-LT/TNF-a antibody was long lived. Several groups of mice were observed for 2-3 mo. None developed disease if it bad not occurred by day 12. In the representative experiment depicted in Fig. 5 , mice were observed for 5 mo after receipt of 7.5 x 106 LNC-8 cells and antibody or PBS . The only mouse in the group of five that received both cells and TN3 .19 .12 to develop clinical signs had a limp tail (grade 1) from day 7 through day 26 and then recovered . Neither it nor any of the other mice in the antibody-treated group developed any further symptoms. In the control group (five mice) that received cells and PBS, four developed clinical signs, one ofthese died on day 12, and the others eventually recovered .
Discussion
The data presented here implicate IT and TNF-a in the passively transferred autoimmune neurological disease EAE .
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We demonstrate that a MBP-specific T cell line produces IT and TNF-a cytotoxic activity after activation with any of several different agents. The biologic activity is neutralized by an anti-LT/TNF-a antibody. The studies reported here are the first antibody neutralization experiments of EAE that provide insight into the identity ofthe mediators of the disease . The extent ofprevention of transfer of EAE was dependent on the dose of anti-LT/ TNF-a antibody used, and these doses (0.3 or 1 mg) were comparable with or less than those used in experiments with other antibodies to inhibit transfer or development of EAE . Sriram et al. (30) used three injections of 3 mg of anti-I-A antibodies on successive days before and after injection ofencephalitogenic T cell clones to inhibit transfer ofEAE . Urban et al. (31) injected 5001.Ag antiV08 antibody to prevent development ofEAE, and Acha Orbea et al. (15) used two 100-ttg injections of anti-VO8 antibody to inhibit T cell transfer ofdisease. In the previous experiments, the design was based on preventing T cell activation (30) or a major component of the T cell repertoire (15, 31) . The experiments reported here represent a different approach to EAE; that is, TN3 .19 .12 inhibits the activity of mediators that are produced in vivo after stimulation of an antigen-specific population ofeffector T cells.
The mechanism by which the anti-LT/TNF-a antibody prevents the transfer ofEAE is under investigation . It is possible that the antibody inhibits the disease in part bybinding to and eliminating TNF-bearing T cells . This possibility is raised by the identification of membrane-bound TNF on a murine CTL clone with a polyclonal rabbit antiTNF antibody (32) , and the demonstration of TNF/cachectin on activated normal human T cells with an anti-TNF mAb (33). We do not believe that this is the most likely explanation for our results, because we have not been able to detect membrane TNF from macrophage lysates with TN3 .19 .12 (18), though we were able to detect a high molecular weight species from membranes ofPU.5.1.8 with a polyclonal antibody (T. James and N. Ruddle, unpublished results) . Moreover, we have not been able to demonstrate surface staining by FACS with TN3 .19 .12 of LNC-8 cells treated identically to those used in the transfer studies. Maximum staining of 106 cells treated with 1, 10, or 100 pg/ml TN3 .19 .12 and a rabbit anti-hamster fluoresceinated antibody was 3.1%; under the same conditions, 94% of the cells were positive by anti-CD3 . Because the concentration of TN3 .19 .12 antibody used in FACS experiments was comparable with that used in the in vivo experiments (i.e., 300 pg/7 x 106 cells), we believe it is unlikely that elimination of TNF-bearing cells is the mechanism . Nevertheless, this possibility exists and is under investigation in in vivo experiments with labeled cells . Histological analysis of tissue from mice that have received LNC-8 cells and TN3 .19.12 has revealed that some treated, clinically normal mice had minimal evidence of cellular infiltrates, while others did not . Thus, the antibody may inhibit transfer at various stages by inhibiting several different activities of the IT and TNF-a secreted by LNC-8 cells . These activities involve a number of effects relevant to the pathogenesis of EAE, including an increase in MHC determinants on endothelial cells (34) , an alteration of central nervous system permeability, and an influx of inflammatory cells through an increase in cell adhesion molecules on the endothelium (34) or astrocytes (35) . Cytokines produced by these inflammatory cells may also directly affect the myelin sheath and influence viability of oligodendrocytes (8) . TN3 .19 .12 antibody could inhibit any of these activities by directly neutralizing secreted IT and TNF-a . Further insight into these questions will derive from experiments underway designed to reverse established disease . Whatever the mechanism(s) by which this antibody inhibits transfer of EAE, this study demonstrates that inhibition of IT and TNF-ct biologic activity prevents transfer of the symptoms of a severe an often fatal neurologic disease. These studies suggest a role for these cytokines or cells that express them in some neurologic diseases. If the transfer of disease in the EAE model is inhibited through inhibiting IT or TNF-ot activity, the studies point the way for the development of TNF antagonists in such disease. The recent cloning of a receptor for IT and TNF-ot (36, 37) elicits cautious optimism regarding feasibility of therapy for cytokine-mediated neurologic disease.
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